Recent Updates
Recently added Catalysts

Niraparib-Bevacizumab

Phase 2

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Biologics | Oncology |Takeda Pharmaceutical Company Limited|Trials Updated: Nov 18, 2026

Niraparib-Bevacizumab development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Feb 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Niraparib-Bevacizumab clinical trials

Niraparib-Bevacizumab · 1 trial · 1 indication

Phase 2 1
NCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorPlatinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
ACTIVE NOT_RECRUITING44 Analytics
PHASE2ACTIVE NOT_RECRUITING
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorUnlock trial analytics

Study Endpoints

Primary Endpoints

progression-free survival(6 months PFS rate)
6 months

To determine the clinical effectiveness of the study treatment assessed using progression free survival(6months) according to RECIST v1.1 criteria (Investigator determined)

Secondary Endpoints

Overall survival (OS)
From the first dose of study treatment until death due to any cause, assessed up to 6 years.
Time to tumour progression (TTP)
Up to 6 years
Time to First Subsequent Treatment (or Death)
The date of first documented first subsequent treatment or date of death, assessed Up to 6 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
experimentalEXPERIMENTALPlatinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous

Interventions

NameTypeDescription
Niraparib-BevacizumabDRUGNiraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W) \*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD.
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites7

\## Inclusion Criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant has a histologically confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed Müllerian carcinoma with a high-grade serous com...

Countries:South Korea
Unlock Eligibility Criteria